BENZTROPINE MESYLATE tablet

Krajina: Spojené štáty

Jazyk: angličtina

Zdroj: NLM (National Library of Medicine)

Aktívna zložka:

BENZTROPINE MESYLATE (UNII: WMJ8TL7510) (BENZTROPINE - UNII:1NHL2J4X8K)

Dostupné z:

American Health Packaging

INN (Medzinárodný Name):

BENZTROPINE MESYLATE

Zloženie:

BENZTROPINE MESYLATE 1 mg

Spôsob podávania:

ORAL

Typ predpisu:

PRESCRIPTION DRUG

Terapeutické indikácie:

For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines). Hypersensitivity to benztropine mesylate tablets. Because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

Prehľad produktov:

Benztropine Mesylate Tablets, USP are available as follows: 0.5 mg: white, round, flat-faced beveled edge, scored tablets, debossed "2325" on one side and debossed "V" on the reverse side, supplied in: Unit dose packages of 100 (10 x 10) NDC 68084-381-01. 1 mg: white, oval, scored tablets, debossed "2326" on one side and debossed "V" on the reverse side, supplied in: Unit dose packages of 100 (10 x 10) NDC 68084-388-01. 2 mg: white, round, flat-faced beveled edge, scored tablets, debossed "2327" on one side and debossed "V" on the reverse side, supplied in: Unit dose packages of 100 (10 x 10) NDC 68084-389-01. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. FOR YOUR PROTECTION: Do not use if blister is torn or broken. *Duvoisin, R.C.; Katz, R.J.; Amer. Med. Ass. 206:1963–1965, Nov. 25, 1968.

Stav Autorizácia:

Abbreviated New Drug Application

Súhrn charakteristických

BENZTROPINE MESYLATE- BENZTROPINE MESYLATE TABLET
AMERICAN HEALTH PACKAGING
----------
BENZTROPINE MESYLATE TABLETS, USP
8238101/1222
RX ONLY
DESCRIPTION
Benztropine mesylate is a synthetic compound containing structural
features found in
atropine and diphenhydramine.
It is a crystalline white powder, very soluble in water, designated as
3α-
(Diphenylmethoxy)-1αH, 5αH-tropane methanesulfonate, with the
following structural
formula:
Each tablet, for oral administration, contains 0.5 mg, 1 mg or 2 mg of
benztropine
mesylate.
Each tablet contains the following inactive ingredients:
croscarmellose sodium, dibasic
calcium phosphate, lactose monohydrate, magnesium stearate and
microcrystalline
cellulose.
CLINICAL PHARMACOLOGY
Benztropine mesylate possesses both anticholinergic and antihistaminic
effects,
although only the former have been established as therapeutically
significant in the
management of parkinsonism.
In the isolated guinea pig ileum, the anticholinergic activity of this
drug is about equal to
that of atropine; however, when administered orally to unanesthetized
cats, it is only
about half as active as atropine.
In laboratory animals, its antihistaminic activity and duration of
action approach those of
pyrilamine maleate.
INDICATIONS AND USAGE
For use as an adjunct in the therapy of all forms of parkinsonism.
Useful also in the control of extrapyramidal disorders (except tardive
dyskinesia – see
PRECAUTIONS) due to neuroleptic drugs (e.g., phenothiazines).
CONTRAINDICATIONS
Hypersensitivity to benztropine mesylate tablets.
Because of its atropine-like side effects, this drug is
contraindicated in pediatric patients
under three years of age, and should be used with caution in older
pediatric patients.
WARNINGS
Safe use in pregnancy has not been established.
Benztropine mesylate may impair mental and/or physical abilities
required for
performance of hazardous tasks, such as operating machinery or driving
a motor
vehicle.
When benztropine mesylate is given concomitantly with phenothiazines,
haloperidol,